Starting Up: What's Attractive To Biotech Investors?

Industry observers maintain that capital is available for companies that have the right formula for success With almost-daily headlines chronicling funding and scientific setbacks to the biotechnology industry, the challenges for scientist- entrepreneurs contemplating making a go of their idea seem daunting, even insurmountable. Yet biotech analysts, officials, researchers, and other observers insist that, despite the depressed financial climate in the industry and investor wariness, capital

| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share


Industry observers maintain that capital is available for companies that have the right formula for success
With almost-daily headlines chronicling funding and scientific setbacks to the biotechnology industry, the challenges for scientist- entrepreneurs contemplating making a go of their idea seem daunting, even insurmountable.

Yet biotech analysts, officials, researchers, and other observers insist that, despite the depressed financial climate in the industry and investor wariness, capital should be available in 1995 for startups with the right formula for success. At the core of this mixture, they say, are sound ideas with high product potential, backed by a solid business plan and a management team that combines scientific savvy with entrepreneurial skills.

"The outlook for startups is surprisingly positive_the terms may be difficult when actually making a deal, but there's a lot more [start-up activity] going on than you would think," maintains Kenneth B. Lee, the national director of the life ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Neeraja Sankaran

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo